Secretory hyperresponsiveness and pulmonary mucus hypersecretion

Chest

Volumn 146, Issue 2, 2014, Pages 496-507

  Rubin, Bruce K ^a   Priftis, Kostas N ^b   Schmidt, H Joel ^a   Henke, Markus O ^c,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; CHOLINERGIC RECEPTOR BLOCKING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXPECTORANT AGENT; FIBRINOLYTIC AGENT; GUAIFENESIN; HEPARIN DERIVATIVE; INTERLEUKIN 13; MACROLIDE; MANNITOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MUCIN 5AC; MUCOLYTIC AGENT; SECRETORY PHOSPHOLIPASE A2; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

AERATION; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTIFICIAL VENTILATION; ASTHMA; ATELECTASIS; BRONCHITIS; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COUGH ASSIST DEVICE; COUGH DOMINANT ASTHMA; CROUPOUS BRONCHITIS; DRUG COST; ENZYME ACTIVATION; HUMAN; INHALATION TEST; LUNG ADENOCARCINOMA; LUNG CLEARANCE; MIDDLE LUNG LOBE SYNDROME; MUCUS SECRETION; NONHUMAN; OSCILLATORY AIRFLOW DEVICE; OSCILLATORY POSITIVE EXPIRATORY PRESSURE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTRACTED BACTERIAL BRONCHITIS; PULMONARY MUCUS HYPERSECRETION; RESPIRATORY EQUIPMENT; RESPIRATORY TRACT DISEASE; REVIEW; SECRETORY HYPERRESPONSIVENESS;

ANIMALS; ASTHMA; AUTONOMIC NERVOUS SYSTEM; BRONCHI; BRONCHOCONSTRICTION; HUMANS; MUCUS;

EID: 84905652411     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2609     Document Type: Article

References (125)

1. Okamoto K, Kim JS, Rubin BK. Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea. Am J Physiol Lung Cell Mol Physiol. 2007;292(1):L62-L67. (Pubitemid 46103430)
2. Webber SE, Kitt A, Yurdakos E, Widdicombe JG. PAF-induced secretory hyperresponsiveness in the ferret trachea to bradykinin and its pharmacological inhibition. Pulm Pharmacol Ther. 1997;10(3):157-166. (Pubitemid 29094858)
3. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev. 2006;86(1):245-278.
4. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest. 2009;135(2):505-512.
5. Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care. 2007;52(9):1134-1146.
6. Li Y, Martin LD, Spizz G, Adler KB. MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro. J Biol Chem. 2001;276(44):40982-40990.
7. Burgel PR, Nadel JA. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J. 2008;32(4):1068-1081.
8. Randell SH, Boucher RC; University of North Carolina Virtual Lung Group. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol. 2006;35(1):20-28. (Pubitemid 43993150)
9. Henke MO, John G, Rheineck C, Chillappagari S, Naehrlich L, Rubin BK. Serine proteases degrade airway mucins in cystic fibrosis. Infect Immun. 2011;79(8):3438-3444.
10. Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol. 2004;31(1):86-91. (Pubitemid 38888043)
11. Innes AL, Carrington SD, Thornton DJ, et al. Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am J Respir Crit Care Med. 2009;180(3):203-210.
12. Kim JS, McKinnis VS, Nawrocki A, White SR. Stimulation of migration and wound repair of guinea-pig airway epithelial cells in response to epidermal growth factor. Am J Respir Cell Mol Biol. 1998;18(1):66-74. (Pubitemid 128355348)
13. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax. 2004;59(11):992-996. (Pubitemid 39490787)
14. Moncada DM, Kammanadiminti SJ, Chadee K. Mucin and Toll-like receptors in host defense against intestinal parasites. Trends Parasitol. 2003;19(7):305-311. (Pubitemid 36833218)
15. Tarang S, Kumar S, Batra SK. Mucins and Toll-like receptors: kith and kin in infection and cancer. Cancer Lett. 2012;321(2):110-119.
16. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L75-L85.
17. Gensch E, Gallup M, Sucher A, et al. Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem. 2004;279(37):39085-39093. (Pubitemid 39296071)
18. Casalino-Matsuda SM, Monzón ME, Forteza RM. Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium. Am J Respir Cell Mol Biol. 2006;34(5):581-591.
19. Thomson NC, Chaudhuri R, Messow CM, et al. Chronic cough and sputum production are associated with worse clinical outcomes in stable asthma. Respir Med. 2013;107(10):1501-1508.
20. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest. 1992;101(4):916-921.
21. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258-2261. (Pubitemid 29004074)
22. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010;363(23):2233-2247.
23. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779-788. (Pubitemid 29152623)
24. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285(3):L730-L739. (Pubitemid 37022875)
25. Kanoh S, Tanabe T, Rubin BK. IL-13-induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells. Clin Exp Allergy. 2011;41(12):1747-1756.
26. Tanabe T, Kanoh S, Tsushima K, Yamazaki Y, Kubo K, Rubin BK. Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells. Am J Respir Cell Mol Biol. 2011;45(5):1075-1083.
27. Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121(3):685-691. (Pubitemid 351323866)
28. Naseer T, Minshall EM, Leung DY, et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med. 1997;155(3):845-851. (Pubitemid 27133392)
29. Zhen G, Park SW, Nguyenvu LT, et al. IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol. 2007;36(2):244-253. (Pubitemid 46233478)
30. Tyner JW, Kim EY, Ide K, et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest. 2006;116(2):309-321. (Pubitemid 43228348)
31. Brightling CE, Saha S, Hollins F. Interleukin-13: prospects for new treatments. Clin Exp Allergy. 2010;40(1):42-49.
32. Zander DS. Allergic bronchopulmonary aspergillosis: an overview. Arch Pathol Lab Med. 2005;129(7):924-928. (Pubitemid 40934314)
33. Oguma T, Asano K, Tomomatsu K, et al. Induction of mucin and MUC5AC expression by the protease activity of Aspergillus fumigatus in airway epithelial cells. J Immunol. 2011;187(2):999-1005.
34. Kuyper LM, Paré PD, Hogg JC, et al. Characterization of airway plugging in fatal asthma. Am J Med. 2003;115(1):6-11. (Pubitemid 36831115)
35. Mochizuki H, Arakawa H, Tokuyama K, Morikawa A. Bronchial sensitivity and bronchial reactivity in children with cough variant asthma. Chest. 2005;128(4):2427-2434. (Pubitemid 41507590)
36. Niimi A, Torrego A, Nicholson AG, Cosio BG, Oates TB, Chung KF. Nature of airway inflammation and remodeling in chronic cough. J Allergy Clin Immunol. 2005;116(3):565-570. (Pubitemid 41267129)
37. Jinnai M, Niimi A, Ueda T, et al. Induced sputum concentrations of mucin in patients with asthma and chronic cough. Chest. 2010;137(5):1122-1129.
38. Laitinen A, Laitinen LA. Cellular infiltrates in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;143(5 pt 1):1159-1160.
39. Ordoñez CL, Khashayar R, Wong HH, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med. 2001;163(2):517-523. (Pubitemid 32158539)
40. Lozewicz S, Wells C, Gomez E, et al. Morphological integrity of the bronchial epithelium in mild asthma. Thorax. 1990;45(1):12-15. (Pubitemid 20046483)
41. Kirkham S, Sheehan JK, Knight D, Richardson PS, Thornton DJ. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J. 2002;361(pt 3):537-546. (Pubitemid 34177823)
42. Temann UA, Laouar Y, Eynon EE, Homer R, Flavell RA. IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells. Int Immunol. 2007;19(1):1-10. (Pubitemid 46017882)
43. Longphre M, Li D, Gallup M, et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest. 1999;104(10):1375-1382.
44. Tanabe T, Fujimoto K, Yasuo M, et al. Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium. Clin Exp Allergy. 2008;38(1):122-134. (Pubitemid 350233391)
45. Li D, Gallup M, Fan N, Szymkowski DE, Basbaum CB. Cloning of the amino-terminal and 5 9 -flanking region of the human MUC5AC mucin gene and transcriptional up-regulation by bacterial exoproducts. J Biol Chem. 1998;273(12):6812-6820. (Pubitemid 28160344)
46. Koo JS, Kim YD, Jetten AM, Belloni P, Nettesheim P. Overexpression of mucin genes induced by interleukin-1 beta, tumor necrosis factor-alpha, lipopolysaccharide, and neutrophil elastase is inhibited by a retinoic acid receptor alpha antagonist. Exp Lung Res. 2002;28(4):315-332. (Pubitemid 34539181)
47. Song KS, Lee WJ, Chung KC, et al. Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem. 2003;278(26):23243-23250. (Pubitemid 36830137)
48. Turner J, Jones CE. Regulation of mucin expression in respiratory diseases. Biochem Soc Trans. 2009;37(pt 4):877-881.
49. Gray T, Coakley R, Hirsh A, et al. Regulation of MUC5AC mucin secretion and airway surface liquid metabolism by IL-1(beta) in human bronchial epithelia. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L320-L330. (Pubitemid 38129513)
50. Gray T, Nettesheim P, Loftin C, et al. Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol Pharmacol. 2004;66(2):337-346. (Pubitemid 38989491)
51. Fujisawa T, Ide K, Holtzman MJ, et al. Involvement of the p38 MAPK pathway in IL-13-induced mucous cell metaplasia in mouse tracheal epithelial cells. Respirology. 2008;13(2):191-202. (Pubitemid 351388781)
52. Chang AB, Redding GJ, Everard ML. Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol. 2008;43(6):519-531. (Pubitemid 351813004)
53. Craven V, Everard ML. Protracted bacterial bronchitis: reinventing an old disease. Arch Dis Child. 2013;98(1):72-76.
54. Marchant JM, Masters IB, Taylor SM, Cox NC, Seymour GJ, Chang AB. Evaluation and outcome of young children with chronic cough. Chest. 2006;129(5):1132-1141.
55. Zgherea D, Pagala S, Mendiratta M, Marcus MG, Shelov SP, Kazachkov M. Bronchoscopic findings in children with chronic wet cough. Pediatrics. 2012;129(2):e364-e369.
56. Marchant J, Masters IB, Champion A, Petsky H, Chang AB. Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax. 2012;67(8):689-693.
57. Everard ML. 'Recurrent lower respiratory tract infections' - going around in circles, respiratory medicine style. Paediatr Respir Rev. 2012;13(3):139-143.
58. Speizer FE, Fay ME, Dockery DW, Ferris BG Jr. Chronic obstructive pulmonary disease mortality in six US cities. Am Rev Respir Dis. 1989;140(3 pt 2):S49-S55. (Pubitemid 19231335)
59. Vestbo J, Prescott E, Lange P; Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med. 1996;153(5):1530-1535. (Pubitemid 26141336)
60. Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology. 2004;45(5):477-484. (Pubitemid 39524322)
61. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653. (Pubitemid 38787999)
62. Melton L. Does mucus hypersecretion matter in airway disease? Lancet. 2002;359(9321):1924.
63. Takeyama K, Dabbagh K, Lee HM, et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A. 1999;96(6):3081-3086. (Pubitemid 29148847)
64. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8(8):1333-1338.
65. Voelkel NF, Tuder R. COPD: exacerbation. Chest. 2000;117(5 suppl-2):376S-379S.
66. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax. 1990;45(8):579-585. (Pubitemid 20270474)
67. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007;176(5):454-459. (Pubitemid 47358099)
68. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol. 2002;2(3):249-255. (Pubitemid 34594363)
69. Ramnarine SI, Haddad EB, Khawaja AM, Mak JC, Rogers DF. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol. 1996;494(pt 2):577-586. (Pubitemid 26318793)
70. Nakaya M, Yuasa T, Usui N. Immunohistochemical localization of subtypes of muscarinic receptors in human inferior turbinate mucosa. Ann Otol Rhinol Laryngol. 2002;111(7 pt 1):593-597.
71. Cammer P, Strandberg K, Philipson K. Increased mucociliary transport by cholinergic stimulation. Arch Environ Health. 1974;29(4):220-224.
72. Gatto LA. Cholinergic and adrenergic stimulation of mucociliary transport in the rat trachea. Respir Physiol. 1993;92(2):209-217. (Pubitemid 23152352)
73. Berger J, Albert RE, Sanborn K, Lippmann M. Effects of atropine and methacholine on deposition and clearance of inhaled particles in the donkey. J Toxicol Environ Health. 1978;4(4):587-604. (Pubitemid 9001477)
74. Abad Santos F, Novalbos J, Gallego Sandín S, Gálvez Múgica MA. Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors [in Spanish]. Med Interna. 2003;20(4):201-205. (Pubitemid 36565485)
75. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther. 2003;98(1):59-69. (Pubitemid 36349761)
76. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):297-304. (Pubitemid 41566939)
77. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax. 1994;49(6):545-548. (Pubitemid 24203156)
78. Pavia D, Sutton PP, Lopez-Vidriero MT, Agnew JE, Clarke SW. Drug effects on mucociliary function. Eur J Respir Dis Suppl. 1983;128(pt 1):304-317. (Pubitemid 13035746)
79. Hasani A, Toms N, Agnew JE, Sarno M, Harrison AJ, Dilworth P. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest. 2004;125(5):1726-1734. (Pubitemid 38648404)
80. Madsen P, Shah SA, Rubin BK. Plastic bronchitis: new insights and a classification scheme. Paediatr Respir Rev. 2005;6(4):292-300. (Pubitemid 41722612)
81. Kruger J, Shpringer C, Picard E, Kerem E. Thoracic air leakage in the presentation of cast bronchitis. Chest. 2009;136(2):615-617.
82. Brogan TV, Finn LS, Pyskaty DJ Jr, et al. Plastic bronchitis in children: a case series and review of the medical literature. Pediatr Pulmonol. 2002;34(6):482-487. (Pubitemid 35375640)
83. Deng J, Zheng Y, Li C, Ma Z, Wang H, Rubin BK. Plastic bronchitis in three children associated with 2009 influenza A(H1N1) virus infection. Chest. 2010;138(6):1486-1488.
84. Moser C, Nussbaum E, Cooper DM. Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle cell disease. Chest. 2001;120(2):608-613. (Pubitemid 32881283)
85. Mateos-Corral D, Cutz E, Solomon M, Ratjen F. Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis. Pediatr Pulmonol. 2009;44(9):939-940.
86. Heath L, Ling S, Racz J, et al. Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. Pediatr Cardiol. 2011;32(8):1182-1189.
87. Peroni DG, Boner AL. Atelectasis: mechanisms, diagnosis and management. Paediatr Respir Rev. 2000;1(3):274-278.
88. Priftis KN, Mermiri D, Papadopoulou A, Anthracopoulos MB, Vaos G, Nicolaidou P. The role of timely intervention in middle lobe syndrome in children. Chest. 2005;128(4):2504-2510. (Pubitemid 41507601)
89. Sekerel BE, Nakipoglu F. Middle lobe syndrome in children with asthma: review of 56 cases. J Asthma. 2004;41(4):411-417. (Pubitemid 38955399)
90. Rubin BK. Editorial: respecting the middle lobe syndrome. Pediatr Pulmonol. 2006;41(9):803-804. (Pubitemid 44300174)
91. Popat N, Raghavan N, McIvor RA. Severe bronchorrhea in a patient with bronchioloalveolar carcinoma. Chest. 2012;141(2):513-514.
92. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18(6):1059-1068. (Pubitemid 34092881)
93. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC, eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004.
94. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285.
95. Kitazaki T, Fukuda M, Soda H, Kohno S. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports. Lung Cancer. 2005;49(1):125-128. (Pubitemid 40798101)
96. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. (Pubitemid 38720929)
97. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
98. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267-5273.
99. Dahlenfors R, Gertzen H, Wedell B, Mark J. Cytogenetical observations in a cultured polymorphous low-grade adenocarcinoma originating from the minor salivary glands. Anticancer Res. 1997;17(1A):105-106. (Pubitemid 27116652)
100. Tonon G, Gehlhaus KS, Yonescu R, Kaye FJ, Kirsch IR. Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas. Cancer Genet Cytogenet. 2004;152(1):15-22. (Pubitemid 38757373)
101. Dinopoulos A, Lagona E, Stinios I, Konstadinidou A, Kattamis C. Mucoepidermoid carcinoma of the bronchus. Pediatr Hematol Oncol. 2000;17(5):401-408. (Pubitemid 30436906)
102. Han SW, Kim HP, Jeon YK, et al. Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer. 2008;61(1):30-34.
103. Yonezawa S, Higashi M, Yamada N, et al. Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int. 2011;61(12):697-716.
104. Rubin BK. Who will benefit from DNase? Pediatr Pulmonol. 1999;27(1):3-4. (Pubitemid 29063794)
105. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552-1560. (Pubitemid 40615404)
106. Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;8:CD001287.
107. LaForce C, Gentile DA, Skoner DP. A randomized, double-blind, parallel-group, multicenter, placebo-controlled study of the safety and efficacy of extended-release guaifenesin/pseudoephedrine hydrochloride for symptom relief as an adjunctive therapy to antibiotic treatment of acute respiratory infections. Postgrad Med. 2008;120(2):53-59.
108. Taylor JA, Novack AH, Almquist JR, Rogers JE. Efficacy of cough suppressants in children. J Pediatr. 1993;122(5 pt 1):799-802. (Pubitemid 23134974)
109. Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology. 2005;10(1):46-56. (Pubitemid 40343762)
110. Daviskas E, Rubin BK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med. 2013;7(1):65-75.
111. Anzueto A, Jubran A, Ohar JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA. 1997;278(17):1426-1431. (Pubitemid 27475971)
112. Bateman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009;22(6):533-542.
113. Kishioka C, Okamoto K, Kim J, Rubin BK. Regulation of secretion from mucous and serous cells in the excised ferret trachea. Respir Physiol. 2001;126(2):163-171. (Pubitemid 32448132)
114. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117(3):393-405.
115. Basbaum C, Li D, Gensch E, Gallup M, Lemjabbar H. Mechanisms by which gram-positive bacteria and tobacco smoke stimulate mucin induction through the epidermal growth factor receptor (EGFR). Novartis Found Symp. 2002;248:171-176.
116. Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011;81(4):265-284.
117. Eason DE, Cox K, Moskowitz WB. Aerosolised heparin in the treatment of Fontan-related plastic bronchitis. Cardiol Young. 2014;24(1):140-142.
118. Reisman JJ, Rivington-Law B, Corey M, et al. Role of conventional physiotherapy in cystic fibrosis. J Pediatr. 1988;113(4):632-636.
119. Main E, Prasad A, Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev. 2005;25(1):CD002011.
120. Willis LD, Warren RH. Acute hypoxemia in a child with neurologic impairment associated with high-frequency chest-wall compression. Respir Care. 2007;52(8):1027-1029.
121. Konstan MW, Stern RC, Doershuk CF. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr. 1994;124(5 pt 1):689-693. (Pubitemid 24161455)
122. Pryor JA. Physiotherapy for airway clearance in adults. E ur Respir J. 1999;14(6):1418-1424. (Pubitemid 30019541)
123. Volsko TA, DiFiore J, Chatburn RL. Performance comparison of two oscillating positive expiratory pressure devices: acapella versus flutter. Respir Care. 2003;48(2):124-130.
124. Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;(1):CD006842.
125. Morsch AL, Amorim MM, Barbieri A, Santoro LL, Fernandes AL. Influence of oscillating positive expiratory pressure and the forced expiratory technique on sputum cell counts and quantity of induced sputum in patients with asthma or chronic obstructive pulmonary disease. J Bras Pneumol. 2008;34(12):1026-1032.